NATCO Pharma Limited announced that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market its generic version of Semaglutide Injection in India. This critical drug is used for treating adults with insufficiently controlled type 2 diabetes mellitus. NATCO plans to launch the product in the Indian market in March 2026, expanding its portfolio of specialty pharmaceuticals and addressing a significant need in diabetes care.
CDSCO Approval Secured for Semaglutide
NATCO Pharma Limited confirmed on February 14, 2026, that it has successfully obtained necessary regulatory approval from the Central Drugs Standard Control Organisation (CDSCO). This approval grants NATCO the authorization to manufacture and market its generic version of Semaglutide Injection within India.
Product Use and Market Launch
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, serving as an important adjunct therapy alongside diet and exercise modifications. NATCO has stated its intention to launch the product commercially in the Indian market shortly, targeting March ’26 for the introduction.
About NATCO Pharma Limited
Headquartered in Hyderabad, NATCO Pharma Limited is an R&D-oriented pharmaceutical company specializing in the development, manufacturing, and distribution of generic, branded, and specialty pharmaceuticals. The company operates 9 manufacturing sites and 2 R&D facilities in India, holding approvals from major global regulatory bodies, including the U.S. FDA and Health Canada, servicing over 50+ global markets.
Source: BSE
